Related Articles
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
Peritumoral overexpression of ZBP‑89 is associated with unfavorable disease‑free survival rates in patients with hepatocellular carcinoma following hepatectomy
Roles of Fascin mRNA expression in colorectal cancer: Meta‑analysis and bioinformatics analysis
LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts